16:HKEX
AS PARTNERS CO LTD
Data as of 2026-03-11 - not real-time
₩1,820.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at 1,820 KRW, modestly above the DCF‑derived fair value of 1,756.78 KRW, suggesting a slight premium. Technicals show the price sitting below the 20‑day SMA of 1,911.7 and the 200‑day SMA of 2,070.57, while the 50‑day SMA remains close at 1,901.02, indicating a neutral to bearish trend. However, the RSI of 31.3 points to oversold conditions and the recent rise in trading volume adds momentum to a potential short‑term rebound toward the resistance around 1,980 KRW. The MACD is in a bearish configuration, with the line well below the signal, tempering optimism about sustained upside. On the fundamentals side, revenue growth of 7.2% is respectable, yet profit margins are razor‑thin (0.4% net margin) and ROE is near zero, raising concerns about earnings durability. The dividend yield stands at an attractive 4.4% with a 20% payout ratio, but the lack of meaningful EPS makes the dividend’s sustainability questionable. Despite a low beta near zero and a 30‑day volatility of about 16.8%, the stock has experienced a maximum drawdown of roughly 24.8%, reflecting notable price swings. Compared with an industry average P/E of 18.2, the company’s price‑to‑sales of 0.53 appears cheap, yet the overall valuation leans toward being overvalued given the DCF gap and weak profitability. In summary, the stock presents a mixed picture: short‑term technical support and a solid dividend contrast with fundamental earnings weakness and a modest premium over intrinsic value.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- RSI in oversold territory (~31)
- Increasing volume trend
- Proximity to resistance level at 1,980 KRW
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Weak profitability and near‑zero ROE
- Dividend yield attractive but sustainability doubtful
- Price still above DCF fair value
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Overvaluation relative to DCF and industry benchmarks
- Persistently low margins and earnings
- Potential downside from max drawdown history (~25%)
Key Metrics & Analysis
Financial Health
Revenue Growth7.20%
Profit Margin0.40%
ROE0.00%
ROA0.25%
Debt/Equity18.81
Op. Cash Flow₩1.8B
Free Cash Flow₩1.1B
Industry P/E18.2
Technical Analysis
TrendNeutral
RSI31.3
Support₩0.00
Resistance₩1,980.00
MA 20₩1,911.70
MA 50₩1,901.02
MA 200₩2,070.57
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair Value₩1,756.78
GradeOvervalued
TypeValue
Dividend Yield4.40%
Risk Assessment
Beta-0.01
Volatility16.76%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
More Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.